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Abstract
Objective Testicular cancer (TC) is the most common
cancer in young men, and its incidence is increasing. The
low mortality rate makes quality of life (QOL) an impor-
tant issue in this patient group. This study aimed to develop
a supplementary module of the EORTC QLQ-C30 ques-
tionnaire to assess TC-specific aspects of QOL.
Methods Questionnaire development was conducted
according to guidelines from the EORTC Quality of Life
Group. Phase I comprised generation of QOL issues relevant
to TC patients through a literature search and interviews with
patients and experts. Phase II included operationalization
and assessment of item relevance. In phase III, items were
pre-tested in a cross-cultural sample to assess issues such as
understandability and intrusiveness of items.
Results In phase I and II, an initial list of 69 QOL issues
possibly relevant to TC patients was refined through patient
and expert interviews. The remaining 37 issues were
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operationalized into items and assessed for relevance and
priority in an expert sample (n = 28) and a patient sample
(n = 62) from Austria, Canada and the Netherlands. After
revision of the item list, 26 items were considered eligible
for pre-testing in phase III, in which 156 patients from
Australia, Austria, Italy and Spain participated. All
items passed criteria for pre-testing, thus forming the new
EORTC QLQ-TC26.
Conclusion The newly developed EORTC QLQ-TC26 is
now available in several languages to assess QOL in TC
patients receiving treatment and in TC survivors. Phase IV
of questionnaire development will comprise international
field testing, including extensive analysis of psychometric
characteristics of the EORTC QLQ-TC26.
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Testicular cancer (TC) is the most common type of cancer
in men aged 15–45 years, and its incidence is increasing [1,
2]. Due to the high survival rate in this cancer population,
preserving quality of life (QOL) and minimizing adverse
effects of cancer therapy are major issues [3–5]. These
issues are particularly important as testicular cancer typi-
cally occurs as men are approaching the peak of their
personal and professional lives, when fertility and family
life are of utmost importance [6].
Treatment for TC usually comprises orchiectomy, with
subsequent therapy depending on tumour histology and
stage [7]. Patients with seminomas often receive additional
radiotherapy [8], but also carboplatin-based chemotherapy
has been shown to be a good alternative for stage I semi-
nomas [9]. Chemotherapy with bleomycin, etoposide and
cisplatin shows very good results for non-seminomas and
seminomas with a stage higher than I [10]. Another therapy
option in case of residual tumour mass after chemotherapy
is retroperitoneal lymph node dissection with nerve sparing
[2, 11].
To date, studies of symptom burden in TC patients have
generally focused on survivors, highlighting a range of
persistent impairments. Physical impairments relating to
chemotherapy side effects include Raynaud’s phenomena
[12, 13], tinnitus [12] and long-term effects such as
increased incidence of cardiovascular disease [14, 15].
Both chemotherapy and radiotherapy impact infertility [16]
and lead to increased fatigue levels [3].
TC survivors’ sexual functioning is impacted by gonadal
dysfunction [17, 18], decreased libido [19], dry ejaculation
[5, 19] and other sexual difficulties [20]. Fegg et al. [19]
also argue that sexual concerns are further aggravated by
inadequate communication about these issues between
doctors and patients. Ozen et al. [21] contend that libido
and erectile dysfunction improved post-treatment, but did
not reach pre-treatment levels. In contrast, ejaculation
problems increased further after cessation of treatment.
To date, a limited number of questionnaires have been
specifically validated for use in TC patients, for example,
to assess neurotoxicity [22], coping [23], marital and sex-
ual satisfaction [24], and QOL [25]. In particular, the QOL
questionnaire developed by Fossa et al. [25] was an
important step towards the comprehensive assessment of
symptoms and functioning in TC patients. This question-
naire has already been used to measure outcomes in an
international trial of the European Organisation for
Research and Treatment of Cancer (EORTC) investigating
QOL in patients with metastatic germ cell cancer [12].
However, as mentioned by Fossa et al. [12], psychometric
testing and extensive translation checks for this question-
naire have not been undertaken. Also, its development did
not follow the detailed EORTC guidelines for question-
naire development guaranteeing cross-cultural applica-
bility and compatibility with the EORTC QLQ-C30.
The EORTC approach to QOL assessment is to use the
EORTC QLQ-C30 for assessing general aspects of QOL
that are relevant to (almost) all cancer patients and to
supplement this core questionnaire with disease-specific
questionnaire modules. So far, a questionnaire module for
TC patients was lacking, limiting the use of the EORTC
QOL measurement system with regard to this patient group.
Thus, the aim of this project was to develop a ques-
tionnaire module as a supplement to the EORTC QLQ-C30
to assess QOL of TC patients in clinical trials and daily
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clinical practice. This questionnaire module was designed
to be applicable to both patients undergoing treatment and
cancer survivors and covers TC-specific issues such as
common treatment side effects, infertility, body image and
sexuality.
Methods
Our study followed the EORTC guidelines for developing
questionnaire modules [26]. These guidelines comprise
four phases: (1) generation of relevant QOL issues, (2)
operationalization of the QOL issues into a set of items, (3)
pre-testing the questionnaire module and (4) large-scale
international field testing.
Phase I-III has now been completed, and the results
from each are presented within this manuscript. The main
steps of the whole development process are summarized in
Fig. 1.
Phase I and II: Generation of relevant QOL issues
and operationalization
An extensive literature search was conducted to establish
an initial list of QOL issues potentially relevant to TC
patients. This list was evaluated in semi-structured inter-
views with experts in the field and with patients to clarify
whether further issues should be included.
The literature search in the databases MEDLINE and
PsychINFO covered the years 1996 to 2006. The following
Fig. 1 Flowchart of the module
development process for the
QLQ-TC26 (according to
[26, 37])
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keywords were used: (testis OR testicular) AND (carci-
noma OR cancer OR neoplasm) AND (quality of life OR
health status OR side effects OR long-term effects OR
symptoms OR radiotherapy OR chemotherapy OR surgery
OR anxiety OR sexuality OR infertility OR body image
OR body mass index, weight change OR information OR
treatment satisfaction OR insurance OR future perspective/
uncertainty).
At this point, we brought forward operationalization of
items (phase II) usually done after phase I to conduct
assessments of specific item text already in patients and
experts already at this stage. QOL issues collected so far
were operationalized into items using a response format
and time frame compatible with the EORTC QLQ-C30.
Pre-existing items from the EORTC Quality of Life Group
Item Bank (covering all items from all development stages
of EORTC modules) were used where possible [27]. The
English items were then translated into the languages of
participating centres to allow collection of patient and
expert ratings. Translation was done according to the
EORTC translation procedure guidelines [28].
Expert and patient ratings of each item were collected
for the following criteria:
• Relevance was rated for each item on a four-point
scale, ranging from ‘‘not at all relevant’’ (1 point) to
‘‘very much relevant’’ (4 points). Relevance refers to
the frequency with which a problem or symptom occurs
and the trouble it may cause.
• Priority for inclusion was rated for each item to identify
those items that affect patients0 QOL most and that
should definitely be included in the final questionnaire.
• Breadth of coverage was investigated by asking
patients and experts to suggest any relevant issues not
included in the item list that should be added.
Items were eligible for inclusion if the mean relevance
scores of patients and of specialists (considered separately)
were 2 or greater and at least 40% of patients and 40% of
specialists gave priority for inclusion. Furthermore, items
were excluded if more than 25% of the answers were missing
(this criterion was not applied to conditional items). These
selection criteria for relevance and priority are similar to
those used in phase I of other EORTC module development
studies [29–31].
Ethical approval was obtained from local ethics com-
mittees at centres contributing patients to phase I and/or
phase III.
Phase III: pre-testing of the module
The pre-testing of the module in a sample of TC patients
from different countries and with different languages
aimed to identify potential problems regarding wording,
comprehensiveness and redundancy or duplications.
Patients were encouraged to comment on each question
(e.g. was it difficult to answer, annoying, confusing,
upsetting or intrusive) and to provide additional concerns
or relevant QOL issues not mentioned in the questionnaire.
Retention criteria for phase III related to patient com-
ments. Items were retained if \10% of patients made any
negative comments about an item and if \5% of patients
made the same negative comment about an item (e.g.\5%
of patients complained about an item being difficult).
In addition, descriptive statistics and preliminary psy-
chometric characteristics for a provisional, content-based
subscale structure were determined. Scores have been lin-
early transformed to a scale range of 0–100, as is common
for EORTC scales.
Results
Phase I and II: generation of relevant QOL issues
and operationalization
The literature search revealed 37 articles and 26 question-
naires providing QOL issues relevant to TC patients. Based
on this literature search and expert discussion, we assembled
an initial list of 20 QOL areas containing 69 issues of
potential relevance to TC patients. This list was edited to
remove overlap and redundancy and was assessed by means
of a semi-structured interview with experts in the field at two
EORTC Quality of Life Group Meetings in 2006. These
experts came from various countries (Austria, Belgium,
Brazil, Germany, Italy, the Netherlands, Norway, Poland and
the UK). Based on this selection procedure, we reduced the
number of QOL issues on the list to 37 (see Table 1).
The 37 issues were operationalized into items with a
response format and time frame compatible with the QLQ-
C30 (as mentioned above, we conducted phase I and II
concurrently). For 25 issues, there were items available
from the EORTC item bank. New items were created to
assess the other 12 issues. These items were translated into
Dutch, German, Italian and Spanish and evaluated by
patients and experts.
Expert ratings on relevance, priority and breadth of
coverage were collected from 28 experts (11 urologists, 6
radiation oncologists, 3 psychologists, 2 medical oncolo-
gists, 2 physicians, 2 junior physicians, a nurse and an
urologist in training). They were working at centres in
Austria (10), the Netherlands (7), Italy (7), Canada (3) and
England (1). Their average years of professional experi-
ence was 11.9 (range 1–35). Items were rated separately for
patients receiving treatment and patients after treatment.
The patient group for item evaluation included 62 TC
patients from Austria (n = 39), Canada (n = 12) and the
372 Qual Life Res (2013) 22:369–378
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Netherlands (n = 11), with a mean age of 39.8 (SD 10.9).
Detailed sociodemographic and clinical data are shown in
Table 2.
Twenty-six of the 37 items met all inclusion criteria
relating to priority, relevance and breadth of coverage. The
remaining 11 items failed to meet one criterion, mainly
patient-rated relevance.
Comments by patients were very rare and therefore did
not have a substantial impact on item selection and item
wording. There were several comments from specialists
regarding the content/wording of items (for item numbers
refer to Table 3). Several items were revised based on the
data collected. For example:
• Item 4 ‘‘Did you have abdominal pain?’’ was changed
to ‘‘Did you have pain in your stomach area?’’ to
increase understandability.
• Item 7 ‘‘Did you experience change in bowel habit as a
result of your disease or treatment?’’ was deleted as this
issue is already covered by the QLQ-C30 questions on
diarrhoea and constipation.
• Item 10 ‘‘Have you had tingling or numbness in your
fingers or toes?’’ was retained, although patients rated the
relevance of this item slightly below two. However, high
expert-rated relevance provided grounds for inclusion.
• Item 13 ‘‘Did you have problems with hearing?’’ also
received a relevance rating below two from patients,
but high relevance ratings from experts supported
inclusion.
• Item 18 ‘‘Have you had any problems with your job
because of your illness?’’was amended to include
education, since a high percentage of patients with
TC are quite young and may be still studying.
Furthermore, we changed the term ‘‘illness’’ to ‘‘disease
or treatment’’ to be consistent with other items.
• Item 24 ‘‘Have you felt less masculine as a result of
your disease or treatment?’’ was retained, despite
narrowly failing to meet the patient relevance criterion,
because otherwise the module would not have covered
the area of body image at all. This item was rated as
highly relevant by specialists.
• Items 28 and 29 concerning weight gain and weight
loss were deleted for several reasons. Experts consid-
ered it more appropriate to measure weight change
using body mass index; weight change over a short
period such as 4 weeks may be negligible for patients
off-treatment (note that a different time frame was used
for these two items); and weight gain and weight loss
can not be combined in a meaningful single scale.
Phase III: pre-testing of the module
The provisional TC module (EORTC QLQ-TC26) derived
from phase II was pre-tested in four countries. From
December 2008 to May 2010, a prospective sample of 156
TC patients was recruited in Austria (n = 74), Italy
(n = 35), Spain (n = 15) and Australia (n = 32). Mean
patient age was 36.8 years (SD 10.5), and mean time since












7. Change in bowel habit
8. Skin problems
9. Irradiated skin discoloured
Peripheral neuropathy 10. Tingling or numbness
fingers/toes
11. Pale/cold fingers/toes
12. Burning/pain in fingers/toes
Difficulty in hearing/tinnitus 13. Problems with hearing
Satisfaction with medical
management
14. Satisfied with care received
Satisfaction with received
information
15. Satisfied with information
received
Future uncertainty 16. Uncertain about future
Loan/Insurance 17. Loan/insurance problems
18. Problems with job
Anxiety of recurrence 19. Anxious about a recurrence
Anxiety of family disruption 20. Disruption of family life
Communication 21. Talk about disease with
partner
Activity 22. Physically limited
Infertility 23. Ability to have children
Body image 24. Less masculine
25. Look at yourself naked
26. Dissatisfied with body
27. Satisfied with testicular
implant
Weight change 28. Lost weight
29. Gained weight
Sexual activity 30. Interested in sex
31. Sexually active
Sexual functioning 32. Felt uncomfortable being
intimate
33. Talk about sexuality
34. Difficulty getting an erection
35. Problems with ejaculation
Sexual enjoyment 36. Was sex enjoyable?
Satisfaction with the sexual
relationship
37. Satisfied with sexual
relationship
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diagnosis was 12.7 months (SD 14.8). Advanced disease
was diagnosed in 25.2% of patients. For further details on
patient characteristics see Table 2.
From the 156 patients who had been interviewed and
had completed the questionnaire, 122 patients (78.2%)
made no comments, whereas 34 patients (21.8%) com-
mented on at least on one item. In total, patients provided
26 item-specific and 12 general comments.
Four patients (2.6%) found at least one question difficult
to understand or answer (item 6 on skin problems and item
7 on pale/cold fingers), and nine patients (5.8%) reported at
least one question to be upsetting, annoying or intrusive
(items concerning sexuality, future uncertainty and body
image). General comments related to the time frame of
7 days being too short and that questionnaires specific to
treatment phases would be preferable. One new issue was
raised referring to the need for information on sperm
banking. It was agreed that this issue is of high importance
before the start of treatment, but no new item was added,
since we considered this issue to be covered by item 10 on
satisfaction with the information received. The two patients
commenting on item 7 (pale/cold fingers) were found to be
patients in aftercare who had not undergone chemotherapy.
The items on future perspective were considered important
as they cover an important psychological parameter com-
monly assessed in cancer patients.
Overall, patients made only a low number of comments
indicating good acceptance and understandability of the
items. All items fulfilled the retention criteria stated in the
methods section.
Table 2 Phase I and III:
Sociodemographic and clinical






Country (language) Australia (English) – 20.5%
Austria (German) 62.9% 47.4%
Canada (English) 19.4% –
Italy (Italian) – 22.4%
the Netherlands (Dutch) 17.7% –
Spain (Spanish) – 9.6%
Age (years) Mean (SD) 39.8 (10.9) 36.8 (10.5)
Range 21-63 18-66
Education Compulsory school or less 10.9% 14.2%
Apprenticeship or professional 34.5% 29.1%
School 38.2% 22.8%
A-level university degree 16.4% 33.9%




Employment Full-time 75.4% 86.7%
Part-time 7.0% 1.7%
In training 3.5% 5.0%
Unemployed 7.0% 2.5%
Other 7.0% 4.1%
Treatment phase On treatment 18.6% 21.0%
\1st year of aftercare 14.0% 35.0%
[1st year of aftercare 67.4% 44.1%
Tumour stage Local 73.6% 74.8%
Advanced 26.4% 25.2%
Surgery Yes 91.2% 91.0%
No 8.8% 9.0%
Radiotherapy Yes 36.8% 10.2%
No 63.2% 89.8%
Chemotherapy Yes 47.4% 60.5%
No 52.6% 39.5%
374 Qual Life Res (2013) 22:369–378
123
Table 3 Phase I: patient and expert ratings of item relevance and priority for inclusion
Phase II items Relevance
ratings
(mean)







1. Did you have hair loss? 2.58 2.45/2.69 75 65/71
2 aDid food and drink taste different from usual? 2.47 2.05/2.21 76 36/31
3 Have you had problems with your sense of taste or smell? 2.19 2.50/2.67 73 52/56
4. Did you have abdominal pain? 2.06 2.55/2.88 63 69/76
5 Have you had heartburn? 2.04 2.45/2.94 53 65/71
6 aDid you have a bloated feeling in your abdomen? 1.90 2.25/2.60 57 58/71
7 cDid you experience change in bowel habit as a result
of your disease or treatment?
2.34 2.36/3.00 65 69/76
8 Have you had skin problems (e.g. itchy, dry)? 2.02 2.55/2.94 65 64/65
9 aIs the skin discoloured around the area that was irradiated? 1.98 2.23/2.44 62 52/53
10 bHave you had tingling or numbness in your fingers or toes? 1.93 2.75/2.87 72 76/75
11 Have you had pale/cold fingers or toes? 2.00 2.38/2.60 68 60/69
12 aDid you have burning and/or pain in your fingers or toes? 1.68 2.43/2.67 58 56/69
13 bDid you have problems with hearing? 1.69 2.81/2.53 56 68/69
14 Were you satisfied with the care you received from your doctors? 3.56 3.27/3.56 92 73/94
15 Were you satisfied with the information you received
about your illness?
3.37 2.91/3.75 84 76/100
16 Did you feel uncertain about the future? 2.68 2.91/3.13 83 65/82
17 aDid you have any loan/insurance problems? 2.11 1.82/1.88 58 46/29
18 Have you had any problems with your job because of your illness? 2.00 2.48/2.88 67 72/71
19 Have you been anxious about a possible recurrence of the disease? 2.91 3.50/3.31 94 96/82
20 Were you concerned about disruption of family life? 2.49 2.86/3.31 79 60/76
21 Can you talk about your disease with your partner or the person
who is closest to you?
3.52 3.00/3.50 94 62/88
22 Have you been physically limited as a result of your
disease or treatment?
2.41 3.09/3.31 90 85/100
23 Were you concerned about your ability to have children? 2.43 3.41/3.81 87 92/100
24 bHave you felt less masculine as a result of your disease or treatment? 1.90 3.14/3.38 71 65/82
25 aDid you find it difficult to look at yourself naked? 1.63 2.64/3.13 49 42/71
26 aHave you been dissatisfied with your body? 1.79 2.77/3.06 52 54/71
27 Answer the question only if you have a testicular implant:
Are you satisfied with your testicular implant?
3.00 3.22/3.60 79 87/83
28 cHave you lost weight? 2.14 2.81/2.53 83 72/47
29 cHave you gained weight? 2.05 2.76/2.44 76 64/41
30 To what extent were you interested in sex? 3.02 2.95/3.19 88 84/81
31 To what extent were you sexually active? (with or without intercourse) 2.66 2.64/2.69 84 73/71
32 aHave you felt uncomfortable about being sexually intimate? 1.98 2.95/3.13 71 69/82
33 Can you talk about sexuality with your partner or the person
who is closest to you?
3.28 2.91/3.31 88 69/76
34 Did you have difficulty getting or maintaining an erection? 2.17 3.23/3.13 84 85/71
35 Did you have problems with ejaculation (e.g. dry ejaculation)? 2.17 3.14/2.94 81 85/71
36 To what extent was sex enjoyable for you? 3.20 2.32/2.38 87 46/53
37 Has the sexual relationship with your partner been satisfying? 3.29 2.59/2.63 85 58/65
a Exclusion due to failing at least one retention criterion
b Inclusion despite failing retention criteria, due to expert comments
c Exclusion due to expert comments, despite fulfilling retention criteria
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Preliminary subscale structure
We conducted a psychometric analysis for a preliminary
content-based subscale structure of the TC module (results
are shown in Table 4). Most scales showed moderate to
good internal consistency, but for the scales Sexual
Enjoyment and Sexual Problems, internal consistency was
relatively low. Detailed analysis revealed that this was
most likely due to strong floor/ceiling effects and therefore
limited item variance. As content appeared to be homo-
geneous, we decided to keep these scales at this stage.
Descriptive statistics for the proposed subscales are
given in Table 4 separately for patients in different treat-
ment phases.
Discussion
The EORTC QLQ-TC26 has been developed to measure
disease and treatment-related QOL issues relevant to TC
patients that are not covered by the EORTC QLQ-C30. The
new module is designed to be administered together with
the EORTC QLQ-C30. Module development in phase I, II
and III was based on extensive literature search, and ratings
and comments from experts and patients and followed the
rigorous validation procedures of the EORTC Quality of
Life Group [26]. To enhance cross-cultural applicability,
patients from various European countries, Australia and
Canada were included in the development process.
Across all development phases, we found that patients
provided only a relatively small number of comments
regarding items, whereas expert feedback and ratings
contributed considerably to decisions on in/exclusion of
items in the final version of the questionnaire. The low
number of comments from patients indicating high accep-
tance may be due to the fact that a high proportion of items
were derived from the EORTC item bank and had conse-
quently already undergone selection procedures within
other EORTC module development studies. As expected, a
few patients expressed problems answering items on sex-
uality. Such items are well known to be problematic as they
are inherently intrusive to some degree. This is often
reflected by low response rates in clinical studies and has
been found in other questionnaire development studies [29,
32, 33]. However, sexual functioning and sexual problems
are important issues for TC patients and expected to have a
particularly high impact on patients’ QOL. Therefore, these
items were kept in the questionnaire module.
For QOL issue generation in phase I, we screened not only
existing questionnaires specific to TC patients or to sexuality
(e.g. the QOL questionnaire from Fossa et al. [25], and the
Prostate Cancer Sexual Scale [34]), but also generic ques-
tionnaires (e.g. FACT-G [35] and the GHQ-28 [36]). As
expected, multi-phase item refinement resulted in exclusion
of most issues from generic questionnaires, as these were
either covered by the EORTC QLQ-C30 core questionnaire
or were only of minor relevance to TC patients. Due to the
extensive nature of the initial item list generated in phase I,
no new issues were included in phase III.
The questionnaire was developed for use not only in
patients currently receiving treatment, but also in long-term
survivors, that is, patients five or more years after treatment.
Table 4 Proposed subscale structure for the QLQ-TC26 after phase III, with internal consistency statistics (Cronbach’s alpha) and descriptive
statistics (item numbers refer to Table 5)





Item Cronbach’s alpha Mean SD Mean SD Mean SD Mean SD
Treatment Side effectsa 01-08 0.78 20.0 12.7 13.9 18.4 8.2 12.1 12.5 15.2
Treatment satisfactionb 09–10 0.85 94.8 11.9 91.8 19.9 79.5 27.6 88.2 22.6
Future perspectiveb 11–12 0.76 48.9 29.0 54.8 25.2 70.4 26.4 60.8 27.8
Job problemsa 13–14 0.80 43.7 33.2 26.4 26.4 18.5 29.9 25.4 30.9
Family problemsa 15 Single item 38.1 38.2 29.9 33.1 26.3 31.4 28.9 32.8
Infertilitya 16 Single item 24.1 39.7 34.7 38.9 31.7 36.5 30.2 37.3
Communicationb 17, 21 0.62 92.2 13.7 82.0 25.9 78.0 27.0 82.9 24.5
Body image problemsa 18 Single item 16.1 27.6 12.2 17.6 19.4 28.0 15.5 24.5
Sexual activityb 19–20 0.79 56.0 33.1 65.6 25.0 64.8 28.6 64.2 28.0
Sexual problemsa 22–23 0.36 11.3 23.9 24.8 29.6 15.5 22.1 20.9 26.5
Sexual enjoymentb 24–25 0.51 76.2 27.7 77.3 25.7 72.5 26.4 73.6 26.4
Testicular Implant Satisfactionb 26 Single item 75.0 50.0 93.3 14.9 60.0 34.7 69.4 35.5
a Symptom scale (high scores indicate high impairment)
b Functioning scale (low scores indicate high impairment)
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As the relevance of specific QOL issues, in particular treat-
ment side effects, changes from time of diagnosis to after-
care, extensive consideration was given to whether or not to
define treatment phase–specific scales. Despite the advan-
tage of avoiding items of potentially limited relevance to the
current situation of an individual patient, we decided against
multiple versions of the questionnaire, as this would have
complicated longitudinal assessments of QOL across the
whole disease trajectory. Also, QOL data collected in phase
III showed that TC survivors more than 1 year from treat-
ment still reported treatment side effects.
Related to this, a limitation of our study was that a large
proportion of patients were in aftercare and were not
undergoing active treatment at the time of assessment.
While this reflects a characteristic of the TC patient pop-
ulation, it limited collection of patient feedback concerning
treatment-related issues. In particular, patients treated with
radiotherapy were underrepresented compared to figures
from the literature [2]. Also, future changes in treatment
strategies (e.g. increasing use of robotic surgery) may lead
to a change in QOL issues relevant to TC patients.
Preliminary analysis of scale structure was primarily
based on content at this stage. For several scales, Cron-
bach’s Alpha as measure of unidimensionality indicated
sufficient item homogeneity. However, the scales Sexual
Enjoyment and Sexual Problems were found to have poor
internal consistency. This might be due to the above-
mentioned presence of floor/ceiling effects in our sample,
but could also lead to splitting these scales into single
items. According to EORTC module development guide-
lines, definitive scale structure will be determined through
field testing in phase IV. For now, we recommend com-
bining these four sexuality items into two scales, as this is
strongly suggested by content.
In conclusion, pre-testing of the EORTC QLQ-TC26 has
been completed successfully. The developed questionnaire
module proved to be applicable for the assessment of TC-
specific QOL issues. Currently, the QLQ-TC26 is available
in English, Dutch, German, Italian and Spanish. The
questionnaire module will be developed further in an
international field study (phase IV) investigating dimen-
sionality, re-test reliability, sensitivity to change as well as
the convergent and discriminatory validity of the scales.
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